Fu B-S, Zhang T, Li H, Yi S-H, Wang G-S, Xu C, Yang Y, Cai C-J, Lu M-Q, Chen G-H
Eur Surg Res. 2011;47(4):218-221. doi: 10.1159/000332827. Epub 2011 Oct 26.
BACKGROUND/AIM: Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for liver transplantation (LT). The present study describes our institutional experience with patients who underwent transplantation for ICC.
A retrospective analysis was performed on 11 consecutive patients with ICC who underwent LT between October 2003 and November 2008 at our institution.
At a median patient follow-up interval of 10 months (2-56), the median survival time was 9 months (2.5-53). The perioperative mortality and the recurrence rate were 0 and 45.5%, respectively. Five patients are currently alive 10, 12, 41, 51 and 53 months after LT, respectively. One patient died 3 months after LT as a result of bile leak and toxic shock, and 5 patients died of tumor recurrences at 2.5, 8, 8, 9 and 10 months post-LT, respectively. The 1-, 2-, 3- and 4-year disease-free survival rates and overall survival rates of all the patients were 51.9, 51.9, 51.9 and 51.9%, and 50.5, 50.5, 50.5 and 50.5%, respectively.
With better and strict patient selection, the prognosis of LT for ICC could be improved. ICC patients with lymph node involvement, vascular or bile duct invasion are contraindicated for LT.
背景/目的：肝内胆管癌（ICC）并非肝移植（LT）广泛认可的适应证。本研究描述了我们机构对接受ICC移植患者的经验。
对2003年10月至2008年11月在我们机构连续接受LT的11例ICC患者进行回顾性分析。
患者中位随访间隔为10个月（2 - 56个月），中位生存时间为9个月（2.5 - 53个月）。围手术期死亡率和复发率分别为0和45.5%。5例患者目前分别在LT后10、12、41、51和53个月存活。1例患者LT后3个月因胆漏和中毒性休克死亡，5例患者分别在LT后2.5、8、8、9和10个月死于肿瘤复发。所有患者的1年、2年、3年和4年无病生存率及总生存率分别为51.9%、51.9%、51.9%和51.9%，以及50.5%、50.5%、50.5%和50.5%。
通过更好且严格的患者选择，ICC患者LT的预后可能得到改善。有淋巴结受累、血管或胆管侵犯的ICC患者禁忌LT。
